Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lactobacillus Johnsonii Supplementation in Adults With T1D
Sponsor: University of Florida
Summary
While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.
Official title: Evaluation of Safety, Tolerability and Immunological Responses to Lactobacillus Johnsonii N6.2 Supplementation in Adults With Diabetes Type 1
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2020-02-01
Completion Date
2026-03-18
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
L. johnsonii Probiotic
Participants will consume one capsule of L. johnsonii probiotic daily for 24 weeks.
Placebo Capsule
Participants will consume one capsule of placebo capsule of dried skim milk daily for 24 weeks.
Locations (1)
UF Clinical Research Center
Gainesville, Florida, United States